DDS vs GMED
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DDS · Dillard's$602.38 ▼ 3.18%
GMED · Globus Medical$71.05 ▼ 12.76%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DDS +3.2%
- GMED -17.7%
Head to head
| Metric | DDS | GMED |
|---|---|---|
| Price | $602.38 | $71.05 |
| Change today | ▼ 3.18% | ▼ 12.76% |
| Market cap | $9.41B | $9.41B |
| Return, 3 months | -4.9% | -17.5% |
| Return, year to date | -0.5% | -18.6% |
| Return, 1 year | +3.8% | -15.3% |
| P/E (TTM) | 13.8 | 17.5 |
| P/B | 4.4 | 2.0 |
| P/E percentile vs own 5y | 86th | 7th |
| Dividend yield | 0.20% | – |
| Revenue growth (YoY, latest qtr) | -0.4% | +5.9% |
| Net profit growth (YoY) | +34.1% | -25.3% |
| Gross margin | 41.2% | 68.5% |
| Operating margin | 11.1% | 21.4% |
| Net margin | 10.3% | 17.0% |
| Return on equity | 33.8% | 11.8% |
| Analyst target vs. price | -3.0% | +41.1% |
| Analyst buy share | 0% | 75% |
| RSI (14) | 38 | 39 |
| 30-day volatility | 46.0% | 61.7% |
| Max drawdown, 1 year | -27.0% | -26.6% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Sell | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GMED is the largest of the group by market value.
- DDS has returned the most over the past year.
- DDS carries the lowest trailing P/E.
- GMED is growing revenue fastest.
- GMED keeps the most profit per dollar of sales.
- DDS has been the calmest stock over the last 30 days.